As our previous study (23) found that age, disease severity, and cumulative days of treatment with recombinant human granulocyte colony-stimulating factor (rhuG-CSF) were risk factors for the evolution of AA into MDS/AML, we performed subgroup analysis. This evidence concerns the gene CSF3 and myelodysplastic syndrome.